MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

XOMA Royalty Corporation - Common Stock (NQ:XOMA)

25.98 -0.33 (-1.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about XOMA Royalty Corporation - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
XOMA Royalty Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
XOMA Royalty adds milestone and royalty economics associated with two partnered assets 
From XOMA Royalty Corporation; LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
Forecasting The Future: 5 Analyst Projections For XOMA Royalty ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On XOMA Royalty Through 4 Analysts ↗
 
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Carisma Therapeutics Inc. (Nasdaq - CARM), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC), Turnstone Biologics Corp. (Nasdaq - TSBX)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Turnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment Slumps ↗
XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock plus one non-transferable contingent value right. 
Via Stocktwits
News headline image
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
From XOMA Royalty Corporation; Turnstone Biologics Corp.
Via GlobeNewswire
News headline image
XOMA Royalty Declares Quarterly Preferred Stock Dividends
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
From XOMA Royalty Corporation; BioInvent
Via GlobeNewswire
News headline image
XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Completes Sale of Kinnate Pipeline Assets
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
The Analyst Verdict: XOMA Royalty In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
XOMA Royalty Declares Quarterly Preferred Stock Dividends
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty to Present at Investor Conferences in March
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Declares Quarterly Preferred Stock Dividends
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
From XOMA Corporation
Via GlobeNewswire
News headline image
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Declares Quarterly Preferred Stock Dividends
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Royalty to Present at Upcoming Investor Conferences in September
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q2 2024 ↗
XOMA stock results show that XOMA missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story